Abstract
Objectives
Breast cancer is the most common malignancy for females worldwide. This study was to evaluate the application of dual-phase breast-specific gamma imaging (BSGI) in detecting primary breast cancer.
Methods
Seventy-six patients with indeterminate breast lesions that underwent dual-phase BSGI enrolled in this study. All included lesions were confirmed by pathology. BSGI was evaluated based on the visual interpretation and dual-phase semi-quantitative indices of lesion to non-lesion ratio (L/N), which were compared with pathological results. The optimal visual analysis and L/N for double-phase were calculated through receiver operating characteristic curve analysis.
Results
Among 76 patients, 92 lesions were finally confirmed by the surgery and pathology, with 54 malignant and 38 benign lesions. Both early and delayed L/N of malignant breast diseases were significantly higher than those of benign (3.18 ± 1.57 vs 1.53 ± 0.59, and 2.91 ± 1.91 vs 1.46 ± 0.54, P < 0.05). The optimal visual interpretation is over grade 3, and cut-off L/N was 2.06 and 1.77 for early and delayed imaging, respectively. Compared with visual analysis over grade 3 (77.8 and 81.6 %), optimal early L/N (81.5 and 92.1 %) or delayed L/N (79.5 and 89.5 %) alone, the sensitivity and specificity of visual combined with early-phase L/N in diagnosing primary breast cancer are higher, which were 85.2 and 92.2 %, respectively.
Conclusions
The combination of visual and semi-quantitative analysis could improve the sensitivity and specificity of BSGI in detecting primary breast cancer. In addition, the potential value of delayed BSGI in diagnosing primary breast cancer should be further investigated in large samples.
Similar content being viewed by others
References
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461–84.
Rosenberg RD, Hunt WC, Williamson M, Gilliland FD, Wiest PW, Kelsey CA, et al. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology. 1998;209:511–8.
Kolb T, Lichy J, Newhuose J. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27, 825 patient evaluations. Radiology. 2002;225:167–75.
Berg WA, Gutierrez L, NessAiver MS, Carter WB, Bhargavan M, Lewis RS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233:830–49.
Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Böhm-Vélez M, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008;299:2151–63.
Kim IJ, Kim YK, Kim SJ. Detection and prediction of breast cancer using double phase 99Tcm-MIBI scintimammography in comparison with MRI. Onkologie. 2009;32:556–60.
Arslan N, Oztürk E, Ilgan S, Urhan M, Karaçalioglu O, Pekcan M, et al. 99Tcm-MIBI scintimammography in the evaluation of breast lesions and axillary involvement: a comparison with mammography and histopathological diagnosis. Nucl Med Commun. 1999;20:317–25.
Palmedo H, Grünwald F, Bender H, Schomburg A, Mallmann P, Krebs D, et al. Scintimammography with technetium-99m methoxyisobutylisonitrile: comparison with mammography and magnetic resonance imaging. Eur J Nucl Med. 1996;23:940–6.
Goldsmith SJ, Parsons W, Guiberteau MJ, Stern LH, Lanzkowsky L, Weigert J, et al. SNM practice guideline for breast scintigraphy with breast-specific gamma-cameras 1.0. J Nucl Med Technol. 2010;38:219–24.
Weigert JM, Bertrand ML, Lanzkowsky L, Stern LH, Kieper DA. Results of a multicenter patient registry to determine the clinical impact of breast-specific gamma imaging, a molecular breast imaging technique. Am J Roentgenol. 2012;198:W69–75.
Lee A, Chang J, Lim W, Kim BS, Lee JE, Cha ES, et al. Effectiveness of Breast-Specific Gamma Imaging (BSGI) for Breast Cancer in Korea: a comparative study. Breast J. 2012;18:453–8.
Melloul M, Paz A, Ohana G, Laver O, Michalevich D, Koren R, et al. Double-phase 99Tcm–sestamibi scintimammography and trans-scan in diagnosing breast cancer. J Nucl Med. 1999;40:376–80.
Arslan N, Ozturk E, Ilgan S, Narin Y, Dundar S, Tufan T, et al. The comparison of dual phase Tc-99m MIBI and Tc-99m MDP scintimammography in the evaluation of breast masses: preliminary report. Ann Nucl Med. 2000;14:39–46.
Paz A, Melloul M, Cytron S, Koren R, Ohana G, Michalevich D, et al. The value of early and double phase 99mTc-sestamibi scintimammography in the diagnosis of breast cancer. Nucl Med Commun. 2000;21:341–8.
Kim SJ, Kim IJ, Bae YT, Kim YK, Kim DS. Comparison of quantitative and visual analysis of Tc-99m MIBI scintimammography for detection of primary breast cancer. Eur J Radiol. 2005;53:192–8.
Taillefer R, Robidoux A, Lambert R, Turpin S, Laperrière J. Technetium-99m sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med. 1995;36:1758–65.
Lu G, Shih WJ, Huang HY, Long MQ, Sun Q, Liu YH, et al. 99Tcm-MIBI mammoscintigraphy of breast masses: early and delayed imaging. Nucl Med Commun. 1995;16:150–60.
Del VS, Salvatore M. 99Tcm-MIBI in the evaluation of breast cancer biology. Eur J Nucl Med Mol Imaging. 2004;31:S88–96.
Conflict of interest
There is no conflict of interest existed.
Author information
Authors and Affiliations
Corresponding authors
Additional information
H. Tan and L. Jiang equally contributed to this work.
This study is supported by National Science Foundation for Scholars of China (Grant No.81271608 to Hongcheng Shi).
Rights and permissions
About this article
Cite this article
Tan, H., Jiang, L., Gu, Y. et al. Visual and semi-quantitative analyses of dual-phase breast-specific gamma imaging with Tc-99m-sestamibi in detecting primary breast cancer. Ann Nucl Med 28, 17–24 (2014). https://doi.org/10.1007/s12149-013-0776-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-013-0776-7